Champions Oncology (CSBR) Receivables - Other (2012 - 2026)
Champions Oncology (CSBR) posted quarterly Receivables - Other of $7.5 million for Q2 2026, up 39.46% year-over-year from $5.4 million in Q2 2025, and up 22.31% quarter-over-quarter from $6.2 million in Q1 2026.
Champions Oncology (CSBR) Receivables - Other (2012 - 2026) Analysis & Trends
Champions Oncology's Receivables - Other history runs 15 years deep, the most recent figure standing at $7.5 million for Q2 2026.
- In Q2 2026, Receivables - Other rose 39.46% year-over-year to $7.5 million; the TTM figure through Apr 2026 stood at $7.5 million (up 39.46% YoY), while the FY2026 annual figure was $7.5 million, up 39.46% from the prior year.
- Receivables - Other for Q2 2026 stood at $7.5 million, up from $6.2 million in the prior quarter.
- The five-year high for Receivables - Other was $7.5 million in Q2 2026, with the low at $3.7 million in Q1 2023.
- The 5-year median for Receivables - Other is $5.2 million (2023), against an average of $5.2 million.
- The sharpest annual moves came in 2023 and 2024: Receivables - Other declined 10.7% in 2023, then soared 65.77% in 2024.
- Champions Oncology's Receivables - Other stood at $4.3 million in 2022, then declined by 7.28% to $4.0 million in 2023, then jumped by 65.77% to $6.6 million in 2024, then climbed by 8.09% to $7.2 million in 2025, then increased by 4.98% to $7.5 million in 2026.
- Business Quant data shows CSBR's Receivables - Other at $7.5 million in Q2 2026, $6.2 million in Q1 2026, and $7.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 7.53 Mn |
| Apr 30, 2026 | 7.53 Mn |
| Jan 31, 2026 | 6.16 Mn |
| Jan 31, 2026 | 6.16 Mn |
| Oct 31, 2025 | 7.17 Mn |
| Oct 31, 2025 | 7.17 Mn |
| Jul 31, 2025 | 5.34 Mn |
| Jul 31, 2025 | 5.34 Mn |
| Apr 30, 2025 | 5.40 Mn |
| Apr 30, 2025 | 5.40 Mn |
| Jan 31, 2025 | 5.79 Mn |
| Jan 31, 2025 | 5.79 Mn |
| Oct 31, 2024 | 6.63 Mn |
| Oct 31, 2024 | 6.63 Mn |
| Jul 31, 2024 | 5.54 Mn |
| Jul 31, 2024 | 5.54 Mn |
| Apr 30, 2024 | 5.94 Mn |
| Apr 30, 2024 | 5.94 Mn |
| Jan 31, 2024 | 4.38 Mn |
| Jan 31, 2024 | 4.38 Mn |